Full text is available at the source.
Abstract
Real-world evidence on glucagon-like peptide-1 (GLP-1) receptor agonists in pediatric obesity is limited.
- Current knowledge about treatment outcomes for pediatric obesity with GLP-1 receptor agonists is sparse.
- Safety data for GLP-1 receptor agonists in children is not well-established.
- Clinical practice patterns regarding the use of GLP-1 receptor agonists in this population require further investigation.
Simplified